PagnatoKarp Partners’s Pfizer PFE Stock Holding History

PagnatoKarp Partners’s Portfolio PFE Stock Details PFE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q2	–	Sell	-59,992	Closed	-$1.86M	–	103
2020 Q1	$1.86M	Buy	59,992 +1,565	+3%	+$53.3K	0.46%	37
2019 Q4	$2.17M	Buy	58,427 +178	+0.3%	+$6.34K	0.38%	40
2019 Q3	$1.99M	Sell	58,249 -320	-0.5%	-$11.6K	0.39%	40
2019 Q2	$2.41M	Sell	58,569 -1,786	-3%	-$70.9K	0.51%	33
2019 Q1	$2.43M	Buy	60,355 +8,892	+17%	+$356K	0.54%	34
2018 Q4	$2.13M	Sell	51,463 -4,372	-8%	-$181K	0.45%	39
2018 Q3	$2.33M	Buy	55,835 +4,465	+9%	+$172K	0.68%	27
2018 Q2	$1.77M	Buy	51,370 +6,735	+15%	+$230K	0.56%	30
2018 Q1	$1.5M	Sell	44,635 -1,039	-2%	-$35.7K	0.63%	28
2017 Q4	$1.57M	Sell	45,674 -944	-2%	-$32.2K	0.46%	32
2017 Q3	$1.58M	Buy	46,618 +1,243	+3%	+$40K	0.4%	30
2017 Q2	$1.45M	Buy	45,375 +752	+2%	+$23.7K	0.44%	32
2017 Q1	$1.45M	Buy	44,623 +1,069	+2%	+$33.7K	0.42%	31
2016 Q4	$1.34M	Buy	+43,554	New	+$1.33M	0.4%	37

Other funds holding PFE

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

PagnatoKarp Partners's PFE Position: Q2 2020 in Review

PagnatoKarp Partners sold out of Pfizer (PFE) in Q2 2020, closing a stake of 59,992 shares — an estimated $1.86M sold.

PagnatoKarp Partners first reported a position in PFE in Q4 2016 and held it in 14 quarters. The position peaked at $2.43M in Q1 2019. 2,442 funds tracked by Wall St. Rank hold PFE as of Q2 2020.

PagnatoKarp Partners reported no remaining Pfizer position as of Q2 2020 after selling out during the quarter.
PagnatoKarp Partners sold 59,992 Pfizer shares in Q2 2020, an estimated $1.86M.
PagnatoKarp Partners first reported a position in Pfizer in Q4 2016 and held it in 14 quarters.
PagnatoKarp Partners's Pfizer position peaked at $2.43M in Q1 2019.
2,442 funds tracked by Wall St. Rank held Pfizer as of Q2 2020.

Based on PagnatoKarp Partners's 13F filing for Q2 2020.